PAT-LM1 Overview

PAT-LM1 is a natural human antibody that has shown great promise in laboratory and animal testing as a potential treatment for multiple types of cancer, with a particularly strong potency against colon, lung, breast, ovary and pancreatic cancers.

Patrys completed the preclinical safety/ toxiciology studies of PAT-LM1 in CY2009.  Importantly, no adverse results were observed in any of the studies, providing the product with a safe profile.  In addition, safety studies performed indicated there was a lack of an immune response against PAT-LM1 by the subjects indicating that it is possible to inject high doses of the product without the subjects “rejecting” the drug, an important characteristic for any product being developed for cancer where treatment may be administered at high doses and over a long period of time.

PAT-LM1 attacks a protein called non-POU domain-containing octamer-binding protein (NONO) which is expressed on 98% of over 200 different types of cancer cells screened.  NONO has been shown to play a role in modulating cell death and repair mechanisms and as a marker in estrogen receptor negative breast cancer tumors. Reports have also observed a strong link between NONO expression and lower survival rate among bladder cancer patients.  In addition, NONO upregulates tumour cell growth and metastases leading to an overall poorer prognosis.

Patrys has now identified the region of binding of PAT-LM1 to the disease target NONO and has filed a patent around this discovery.

The Company has successfully established commercial scale manufacturing for PAT-LM1 in the proprietary PER.C6® cell line.  Patrys may commence a first-in-human clinical trial for PAT-LM1 in 2012, subject to financing and/or partnering status.

Recent PAT-LM1 Milestones

• Adaptation to Patrys’ proprietary manufacturing platform
• Completion of preclinical development including toxicology studies

Upcoming PAT-LM1 Events

• Completion of manufacturing to support clinical trial
• Commencement of Phase I clinical trial as either internal or partnered product